class = “cf”>
Chairman and CEO of Biontech (CEO) and co-founder Prof. Dr. Uğur Şahin, Professor of Immunology at the University of Modena Andrea Cossarizza, Professor of Immunology at Stanford University Mark Davis attended.
Speaking at the event, ahin shared information about lab processes and studies of the mRNA vaccine they have developed against the new type of coronavirus (Kovid-19). Stating that he tried different approaches throughout the process and obtained the necessary proof of concept by performing the first clinical studies, Şahin stressed that there are many documents in clinical studies and that they must be prepared separately for each patient.
Pointing out that the production of GMP (granulocyte-monocyte progenitor) is a ‘boring’ process, ahin said, “What we did was this. We turned them into electronic recording, batch recording and automation of the approach. six weeks. ” he said.
“Dealing with the 2020 pandemic has allowed us to use these technologies and the goal of developing a vaccine.” Şahin said the concept they used here is the same and that they are using genetic information to protect themselves against the virus.
Şahin said, “We have tested over 20 neurogens, and we also asked which vaccine is the most suitable, and we saw if the best receptor binding site or the complete spike protein was the most suitable vaccine. ” he said.
“WE WILL PRODUCE OVER A TRILLION Doses of vaccine by the end of the year”
Stating that they have data measuring the effects of vaccines at 2 and 6 months, Ahin said, “Our vaccine production was 10,000 in 2019. Together with our partner Pfizer, we will produce over 1,000 billion doses of vaccine. by the end of the year. It is a huge increase. ” noted.
Şahin said, “We regularly analyze the cost neutralization of variants. We have observed that the localization of the delta variant has decreased, but everything is fine. Used the expression.
Stating that he obtained this data 2 months after the second dose, ahin said:
“We are seeing an increased time interval in antibody titer after the second dose and this protection against the Delta variant also lowers the antibody titers. We still have strong protection against disease. We have also seen it. This is unpublished data, complete neutralization, higher antibody titers after the second dose. The supplement is provided after the third dose. Data show that 95 percent of the third dose provides protection complete and 97 percent infection control.
This guide guides gastronomy enthusiasts